Manipal Journal of Pharmaceutical Sciences
Volume 5

Issue 2

Article 4

1-9-2019

Development of sustained release in situ nasal gel of ondansetran
HCl using mucoadhesive polymers
Jagadeesh R
Department of Pharmacology, Sree Siddaganga College of Pharmacy, Tumakuru, Karnataka

Ashok Kumar
Department of Pharmacology, Sree Siddaganga College of Pharmacy, Tumakuru, Karnataka,
ashokkumarscp@gmail.com

Manjunath K
Department of Pharmaceutics, Sree Siddahanga College of Pharmacy, Tumakuru, Karnataka

Mancy S P
Department of Pharmaceutics, Sree Siddahanga College of Pharmacy, Tumakuru, Karnataka

Follow this and additional works at: https://impressions.manipal.edu/mjps

Recommended Citation
R, Jagadeesh; Kumar, Ashok; K, Manjunath; and S P, Mancy (2019) "Development of sustained release in
situ nasal gel of ondansetran HCl using mucoadhesive polymers," Manipal Journal of Pharmaceutical
Sciences: Vol. 5 : Iss. 2 , Article 4.
Available at: https://impressions.manipal.edu/mjps/vol5/iss2/4

This Research Article is brought to you for free and open access by the MAHE Journals at Impressions@MAHE. It
has been accepted for inclusion in Manipal Journal of Pharmaceutical Sciences by an authorized editor of
Impressions@MAHE. For more information, please contact impressions@manipal.edu.

R et al.: Development of sustained release in situ nasal gel of ondansetran
Kumar AP, et al: Development of sustained release in situ nasal gel of ondansetran...

Research Article

Development of sustained release in situ nasal gel of
ondansetran HCl using mucoadhesive polymers
Jagadeesh R, P Ashok Kumar*, K Manjunath, Mancy S P
Email: ashokkumarscp@gmail.com

Abstract
In situ gel dosage forms are solutions after administration undergoes gelation to form a gel. The objective of the
current study is to develop, characterize and evaluate nasal in situ gel containing anti-emetic drug of OND-HCl®
by a temperature induced method. In this method, Lutrol F-127®, is used as a thermos-reversible polymer, PVP
K30®, HPMC K4M® and PEG 6000® as mucoadhesive polymers. The tests for gel formation, pH, viscosity, in
vitro drug diffusion, drug content, gelation temperature, gelation time and mucoadhesive force were conducted
for the developed formulations. The percentage drug content and pH of all the formulations were found to be in
the range of 95% - 99% and 4.9-5.2, respectively. Considering the in vitro drug diffusion studies formulation, F7
was optimized. It is an effective formulation exhibiting a sustained drug diffusion of 93.98% for eight hours with
viscosity 30 and 20 cps. From the results it is concluded that OND-HCl® nasal in situ gel produces a prolonged
drug delivery for the treatment of chemotherapy induced nausea and vomiting.
Key words: In Vitro Drug Diffusion, FTIR, Nasal In Situ Gel, Ondansetron HCl

Introduction
OND-HCl® is a serotonin sub type-3
(5-hydroxytryptamine-3) receptor antagonist. It is
an extensively exploited drug for the treatment of
several therapeutic purposes like antiemetic, it is
especially used in the prevention of post-operative
nausea and vomiting (PONV), chemotherapy
induced nausea and vomiting, (CINV) or radiation
induced nausea and vomiting.1 Bioavailability
of drug is 50-60%, a half-life of 4-6 hours, and
undergoes metabolism in the liver via CYP3A4,
CYP1A2, CYP2D6. Intranasal delivery seems to
be an alternative route of administration during
such conditions. However, the drug resides in the
nasal cavity for a short duration, which affects the
absorption and bioavailability of the drug. Hence,
while designing the nasal dosage forms, anatomic
and physiologic characteristics of nasal mucosa and
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rapid mucocilliary clearance (MCC) that limits the
time offered for the absorption of the drug from the
applied dosage form has to be considered.2,3 So, to
lengthen/increase the residence time available at
the nasal absorption site and thereby assist the drug
uptake, a promising approach is to decrease MCC
rapidly, by using/with the help of mucoadhesive
formulations. Ordinary gels are inconvenient to
administer and an accurate measurement of the
drug dose is also not possible.4 A nasal mucoadhesive
in situ gel is found to be very attractive because of its
fluid-like state prior to the nasal administration, and
can thus be easily administered as a drop permitting
accurate drug dosing. Thermosensitive smart
polymers were used to achieve in situ gelation, which,
upon sensing the nasal temperature, transforms into
gel after instillation.5 Thermo-reversible polymer
used in the formulation of thermosensitive in situ
nasal gel must have gelation temperature around
nasal physiological temperature range (29°C to
34°C). Lutrol F127 (LF127®) has a tremendous
thermosensitive gelling property, excellent
water solubility, low toxicity, good drug diffusion
characteristics and good chemical compatibility.
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Lutrol F127® is an ABA triblock copolymer
comprising the hydrophobic polypropylene
oxide and hydrophilic polyethylene oxide (PEO).
LF127® exists as a viscous mobile liquid at a lower
temperature but upon increasing the temperature
a rigid semisolid gel network is formed, showing
a temperature induced gelation.6 Developing the
OND-HCl® mucoadhesive thermo-reversible in situ
nasal gel with enhanced nasal residence time and
absorption through the nasal mucosal membrane,
thereby enhancing the bioavailability of the drug, is
the objective of the current study.
Materials and methods
Materials: OND-HCl® obtained from Swapnroop
drugs and Pharmaceuticals, Mumbai, India. Lutrol
F-127®, HPMC K4M®, PVP K30® obtained from
HI Media Laboratories Pvt Ltd, Mumbai, India,
and PEG 6000®, Benzalkonium chloride® were
obtained from SD Fine Chem Laboratories Pvt Ltd,
Maharastra, India.
Preparation and optimization of thermoreversible LF127® gels:
The plain and drug-loaded LF127® gels were
prepared by a cold method described by Schmolka.
et al.6 For drug-loaded LF127® gels, the drug was
stirred with a sufficient quantity of 0.01N citric

acid and kept overnight at 4°C in a refrigerator.
LF127® was then added slowly with continuous
stirring, and finally the volume was adjusted. The
dispersions were then stored in a refrigerator until
a clear solution was obtained. Optimization of plain
and drug-loaded LF127® gel was done by varying
the concentration of LF127® and evaluating them
for the gelation temperature. Batches containing
optimized concentration of LF127® are used for
further investigation. Three different concentrations
of mucoadhesive polymers were screened. HPMC
K4M® (0.5% to 1.5%), PVP K30® (0.1% to 0.5%),
and PEG 6000® (0.1% to 0.5%) were tried as a
mucoadhesive polymer.6 Plain LF127® was prepared
following the same method omitting the drug.
Preparation of mucoadhesive thermo-reversible
nasal gels:
OND-HCl®,
mucoadhesive
polymer,
and
Benzalkonium chloride® were dissolved in 4 mL of
0.01N citric acid by agitation at room temperature.
The optimized concentration of LF127® in the final
formulation is 18% w/v. After cooling the solution
to 4°C, a specified amount of LF127® i.e., 1.8 g, is
dissolved in 3 mL of 0.01N citric acid solution, and
this was added completely and slowly with agitation
to the drug and the polymer solution. Finally, the
volume was adjusted by using cold distilled water.

Table 1: Effect of Concentration of LF127® (Poloxamer407) on gelation temperature.
Ingredients

G1

G2

G3

G4

G5

G6

G7

G8

G9

G10

OND-HCl® (g)

-

-

-

-

-

0.1

0.1

0.1

0.1

0.1

Lutrol F-127®, (g)

1.6

1.7

1.8

1.9

2.0

1.6

1.7

1.8

1.9

2.0

Distilled water (mL) q.s. to

10

10

10

10

10

10

10

10

10

10

Gelation temperature observed (°C)

45

37

26

24

20

50

42

35

30

26

Table 2: Formulation of OND-HCl® nasal in situ gel (F1) to (F9)

24

Ingredients
Ondansetron HCl (g)
Lutrol F-127®, (g)
PVP K 30 (g)

F1
0.1
1.8
0.01

F2
0.1
1.8
0.03

F3
0.1
1.8
0.05

F4
0.1
1.8
-

F5
0.1
1.8
-

F6
0.1
1.8
-

F7
0.1
1.8
-

F8
0.1
1.8
-

F9
0.1
1.8
-

HPMC K4M® (g)

-

-

-

0.01

0.03

0.05

-

-

-

PEG 6000® (g)

-

-

-

-

-

-

0.05

0.1

0.15

Propylene glycol
(mL)

0.8

0.8

0.8

0.8

0.8

0.8

0.8

0.8

0.8

Benzalkonium chloride® (mL)

0.002

0.002

0.002

0.002

0.002

0.002

0.002

0.002

0.002

Distilled water
(mL) q.s to

10

10

10

10

10

10

10

10

10
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The resulting dispersion was then kept at 4°C
overnight until a clear transparent solution was
formed.7,8 (Table 1 followed by Table 2)
Compatibility studies (FT-IR spectroscopic
studies):
Compatibility between the drug and polymer were
studied by using FTIR spectrophotometer (JASCO
460+). Infrared spectra of all the ingredients used
in the formulation are scanned individually. Also,
the infrared spectrum of physical mixture drug and
polymers are scanned between 4000 cm-1 to 400 cm-1.
Characteristic peaks of OND-HCl® are mentioned
in the Table 3. These characteristic peaks are
retained in the spectra of drug and physical mixture.
Thus, after a perusal of Figure 3 to 7 and Table 3, it
is clear that there is no interaction between the drug
and polymers used.
Figure

3

4

5

6

7

FTIR
Spectrum

Peak
at wave
number
(cm-1 )

Functional groups

3407.6
3175.22
1637.27
1631.2
1458.89
1281.47

-OH stretching
-CH Ar stretching
>C=O stretching
>C=C<Ar stretching
-CH2 bending
-CH3 bending

3402.6
3040.23
1637.27
1536.99
1466.6
1280.5

-OH stretching
-CH Ar stretching
>C=O stretching
>C=C<Ar stretching
-CH2 bending
-CH3 bending

3412.42
3175.22
2948.63
1637.27
1581.2
1482.03
1281.47

-OH stretching
-CH Ar stretching
-CH Ali stretching
>C=O stretching
>C=C<Ar stretching
-CH2 bending
-CH3 bending

ONDHCl® +
HPMC
K4M®

3417.24
3175.22
1638.23
1531.2
1479.13
1280.5

-OH stretching
-CH Ar stretching
>C=O stretching
>C=C<Ar stretching
-CH2 bending
-CH3 bending

ONDHCl®
+ PEG
6000®

3492.33
2697.93
1637.27
1536.99
1466.6
1280.5

-OH stretching
-CH Ar stretching
>C=O stretching
>C=C<Ar stretching
-CH2 bending
-CH3 bending

ONDHCl®

ONDHCl® +
Lutrol
F-127®,

ONDHCl® +
PVP K 30®

Clarity
The clarity of various formulations was determined
by visual inspection under black and white
background with letters on a contrast colour, and it
was graded as follows: turbid, +; clear, ++; and very
clear (glassy), +++. The solution is graded as clear
when the view of the letters in the background is
prominent, and the solution is graded as very clear
when the view of the letters in the background is
most prominent.
pH of formulation
pH meter (Equiptronics, Model EQ-610), which was
calibrated using solutions of pH 4.5 and 7, is used to
measure the pH of all the formulations.9
Gelation temperature
Visual observation method:
2 mL of the formulation was taken in a test tube and
immersed in a water bath in which the temperature
was increased from the room temperature at a
constant rate of 1°C every two minutes until the gel
is formed. Then the test tube was tilted at an angle
of 90° to observe the movement of the meniscus; if
there is no movement of the meniscus, the gelation
of the sample is confirmed.10
Gelation time:
For assessing the gelation time, a glass slide was used.
Provision was made to keep the slide in hot water for
about 15-20 minutes for equilibrating temperature
(37°C). One drop of the formulation was placed on
the glass slide which was maintained at an angle of
120°, and the time taken for converting it into gel
was recorded.7 (Figure 1)

Figure 1: Photography taken during the measurement of gelation
time
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Viscosity measurement of the nasal in situ gel:
Viscosity of the prepared formulations was measured
by using Brookfield LVDV-E Viscometer using
spindle RV/HA/HB/-1 at 25°C. The spindle was
lowered perpendicularly into 50mL volume of gel,
which was to be measured. The spindle is rotated at
50 rpm speed, and the viscosity of the preparation
is measured.11

Figure 2: Modified chemical balance used for determination of
mucoadhesive strength of formulation.

Determination of drug content:
The drug content is determined by taking 1 mL of
the formulation and 2 mL of methanol in a 100 mL
volumetric flask, which contained a few mL of nasal
simulated fluid in. It was stirred vigorously. Then, it
was made up with nasal simulated fluid up to 100 mL.
From the above solution, 10 mL was withdrawn and

further diluted to 100 mL with nasal simulated fluid.
The absorbance of the above solution was measured
at 248 m by using UV-Vis spectrophotometer
(Shimadzu UV- 1800).12,13
Determination of mucoadhesive force:
The mucoadhesive strength of each formulation was
determined by measuring the force required to detach
the formulation from a goat nasal mucosal tissue by
using a modified chemical balance. A section of the
nasal mucosa was cut from the goat’s nasal cavity
and the mucosal side was instantly fixed into each
glass vial using a rubber band. The vials with nasal
mucosa were stored at 37°C for 5 minutes. Then, the
next vial with a section of mucosa was connected
to the balance in an inverted position while the
first vial was placed on a height-adjustable pan. A
fixed amount of sample of each formulation was
placed onto the nasal mucosa of the first vial. Then,
the height of the second vial was adjusted so that
mucosal surfaces of both vials come into an intimate
contact. Two minutes contact time was given to
ensure an intimate contact between the sample and
tissues. Then, the weight was increased in the pan
until the vials got detached. The bio adhesive force,
expressed as the detachment stress in dyne/cm2, was
determined from the minimal weights that detached
the tissues from the surface of each formulation
using the following equation. The nasal mucosa was
changed for each measurement. (Figure 2)
Where, m =Weight required for detachment of two
vials in gm

Figure 3: FT-IR spectrum of pure drug OND-HCl®
26

Manipal Journal of Pharmaceutical Sciences | September 2019 | Volume 5 | Issue 2

https://impressions.manipal.edu/mjps/vol5/iss2/4

4

R et al.: Development of sustained release in situ nasal gel of ondansetran
Kumar AP, et al: Development of sustained release in situ nasal gel of ondansetran...

g = Acceleration due to gravity [980 cm/s2]
A = Area of tissue exposed
The nasal mucosa was changed for each
measurement. (Figure 2)
In vitro drug diffusion studies:
2 mL of the formulation was taken in a glass tube
of diameter 2 cm and tightly covered with dialysis
membrane (Hi-Media, pore size 2.4 nm). Then, the
boiling tube was inverted and tied to the paddle
of the USP type II dissolution apparatus. Nasal
simulated fluid was taken as a dissolution medium.
The paddle’s height was adjusted as the dissolution
medium taken was 250mL and maintained at a
temperature of 37 ± 0.5°C, with the speed of 50
rpm.
2 mL of the sample was withdrawn at 1 hour
intervals for up to 8 hours. A fresh medium is
replaced to maintain the sink condition. The

samples are suitably diluted and analyzed by a UV
spectrophotometer at 248 nm using nasal simulated
fluid as a blank. The drug concentration is calculated
by a calibration curve,
Results and discussion
FT-IR spectra
FT-IR spectrum of the pure drug OND-HCl® is
shown in Figure 3. FT-IR spectra of the physical
mixture of the drug with different polymers like
Lutrol F-127®, PVP K 30®, HPMC K4M®, PEG
6000® are shown in Figures 4 to 7. The characteristic
peaks of the drug are observed in the spectra of
mixture of the drug and the polymer. However, the
intensity of the peaks are reduced, and this might be
due to a very low concentration of the drug in the
mixture. This indicates that there is no interaction
between the drug and the polymer. (Table 3 and,
Figures 3, 4, 5, 6 and 7)

Figure 4: FT-IR spectrum of pure drug OND-HCl®+ Lutrol F127®

Figure 5: FT-IR spectrum of pure drug OND-HCl® + PVP K 30®
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Table 4: Characterization of OND-HCl® in situ nasal gel formulations.
Parameter
Clarity
pH
Gelling temperature

F1
+++
5.1
34

F2
+++
5.0
33

F3
+++
5.2
33

F4
+++
5.1
32

F5
+++
4.9
32

F6
+++
5.0
31

F7
+++
5.0
35

F8
+++
4.9
37

F9
+++
5.0
40

(°C)
Gelling time (Sec)
Drug content (%)
Muco-adhesive force

6
98
936.3

11
99
1248.4

14
99
1560.5

6
95
1248.4

6
96
1248.4

7
98
1560.5

13
97
2808.91

14
95
3121.01

15
98
3433.12

(dyne/cm2)
Viscosity (cps)

26.7

29.5

33.3

30.0

66.2

100.0

20.0

22.1

23.7

Table 5: Percentage drug diffusion of OND-HCl® formulations prepared with three different polymers.
TIME
in hrs

Polymers used for preparation
F1

F2
6.16

0.5

13.33

1

30.44

2

79.21

3

98.80

4

-

99.95

5

-

-

6

-

-

7

-

-

8

-

-

30.14
65.14
86.42

F3
6.9
27.02
57.68
82.39
96.98
99.03

F4
9

F5
6.62

25.07

15.38

42.72

31.29

58.11

51.35

67.32

52.70

76.60

69.06

83.45

71.70

86.60

73.09

92.27

88.23

F6
6.5
12.80
21.27
32.82
43.08
52.17
61.33
66.81
74.83

F7
11.12

F8
9.5

F9
8.5

22.08

21.95

16.31

62.76

51.50

35.19

69.41

68.26

47.97

76.84

73.80

60.85

89.38

78.69

65.08

89.54

79.96

70.59

91.33

80.55

73.64

93.98

91.17

81.71

Preparation of nasal in situ gel
Initially, we tried to prepare nasal in situ gel
of ODN-HCL® by three methods i.e., by a pH
induced method, an ion induced method, and by a
temperature induced method. In the pH induced
method, carbopol was selected as the gelling agent.
While adding the drug solution into the carbopol
solution, the drug started to solid out immediately,
showing incompatibility.

All the formulations were prepared using the
ingredients given in Table 2 for the temperature
induced method. The final volume of the formulation
was adjusted with cold distilled water because
the poloxamer 407 showed greater solubility at a
lower temperature (5°C) when compared to room
temperature. This is because poloxamer 407 forms
an excessive hydrogen bonding between the water
and its ethereal oxygen.8

With the ion induced method, gellan gum was used
as a gelling agent during the mixing of the drug
solution and gellan gum solution. Because of the
ionic nature of the OND-HCl®, the precipitation
occurred, showing incompatibility. So the ion induced
method was also not suitable for the preparation of
the OND-HCl® nasal in situ gel.

Characterization of OND-HCl® in situ nasal gel
formulations.
All nine formulations of OND-HCl® in situ gel
were found to be clear. The pH of the in situ gelling
solution was found to be 4.9 to 5.2. The viscosity of in
situ nasal gel formulation was in the following order:
formulations with HPMC K4M®; ˃ formulations
with PVP K30®; ˃ and formulation with PEG
6000®. Gelation temperature range suitable for
nasal gel was 32–35 °C. As the concentration of the
Lutrol F127 was increased, gelation temperature
was decreased, as shown in Table 1. Gelation

Whereas, in the case of the temperature induced
method, using Lutrol F-127® as a thermo-reversible
polymer turned out to be a suitable method for the
preparation of OND-HCl® nasal in situ gel.
28
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Figure 6: FT-IR spectrum of pure drug OND-HCl® + HPMC K4M®

Figure 7: FT-IR spectrum of pure drug OND-HCl® + PEG 6000®

temperature of the prepared formulation (F1 to F9)
was in the range of 31° to 40 °C. Gelation time of
the prepared formulation was in the range of 6 to 15
seconds. The drug content was estimated for all the
batches and it was found to be in the range of 95 –
99.98%, as shown in Table 4.
It shows that as the concentration of PVP K30®,
HPMC K4 M and PEG 6000® increased, the
mucoadhesive strength increased as well, as shown
in Table 4. The mechanism of mucoadhesion can be
attributed to the hydrogen bonding between the gel
formulation and oligosaccharide chains of mucosal
membrane (via carboxyl groups of PVP K30®,
Hydroxyl group of PEG 6000®). The mucoadhesive
force of the prepared formulation is in the range of
936.3 dyne/cm2 to 3433.12 dyne/cm2. (Table 4)
In vitro drug diffusion study:
Nine formulations of OND-HCl® nasal in situ
gels were prepared using three mucoadhesive

polymers such as PVP K30®, HPMC K4M®
and PEG 6000®. Each polymer was used at
three different concentrations (0.1, 0.3 and 0.5%
w/v). The percentage of the drug diffusion for
all nine formulations is shown in Table 5, and the
dissolution profiles are shown in Figures 8 to 10.
Upon increasing the percentage of polymer, the
drug diffusion was decreased. After 8 hours of
diffusion studies, it was found that the formulation
F7 diffusion has the maximum percentage of drug
i.e,, 93.98%. Hence, the formulation was optimized
(Table 5, and Figures 8, 9 and 10).
Conclusions
In this study, sustained diffusion nasal in situ gels
of OND-HCl® was prepared by thermo-reversible
mechanism, using Lutrol F-127®, (polaxamer 407)
as a gelling agent, and PVP K30®, HPMC K4 M
and PEG 6000® as mucoadhesive polymers. It was
found that an increase in the concentration in the
polymeric ratio decreases the drug diffusion and
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was able to sustain for 8 hours. The formulation F7,
containing 18% Lutrol F-127®, & 0.5% PEG 6000®,
showed a good drug diffusion over a period of 8
hours. These entire formulations showed acceptable
results for Viscosity, pH, drug content, gelling
temperature, gelling time, mucoadhesive force, etc.
Thus, formulation F-7 was found to be the most
promising formulation on the basis of acceptable in
situ gelling properties and drug diffusion studies.

Figure 8: In vitro drug diffusion profiles of F1- F3 formulation
prepared with polymer PVP K30®.

Figure 9: In vitro drug diffusion profiles of F4- F6 formulations
prepared with polymer HPMC K4M®.

Figure 10: In vitro drug diffusion profiles of F7- F9 formulations
prepared with polymer PEG 6000®.
30

Among all the three methods, pH induced method
and ion induced method were not suitable, especially
for OND-HCl® due to incompatibility problems.
The temperature induced method was able to
produce in situ nasal gel of OND-HCl with the help
of LF127® as a thermos-reversible polymer.
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